Loading...
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
BACKGROUND: Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important...
Saved in:
| Published in: | World J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Baishideng Publishing Group Inc
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522768/ https://ncbi.nlm.nih.gov/pubmed/31139312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i5.424 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|